Novo Nordisk Faces a Three-Front November: Courtroom Setback, Lilly's Rising Tide and the 4 November Print

Novo Nordisk's autumn is shaping up as a test of how well investors can keep separate ledgers. A US judge declined on 26 October to grant the Danish drugmaker a preliminary injunction against Eli Lilly's contested advertising for weight-loss medicines, Reuters reported — a procedural loss that says nothing about the merits of the underlying claims, which continue to be litigated. The ruling means Lilly may keep running the challenged campaigns while the case proceeds; it is neither a final defeat for Novo nor a judicial endorsement of Lilly's marketing.

That distinction matters because the legal skirmish is unfolding alongside a far more consequential contest over clinical data and commercial momentum. On Wednesday, Lilly reported positive Phase 3 results from TRANSCEND-T2D-2, saying its retatrutide outperformed Novo's Ozempic on weight loss and A1C reduction in adults with type-2 diabetes. The readout weighed on sentiment toward Novo. A day later, media reports said Lilly had lifted its 2026 revenue guidance to $91 billion–$92 billion, citing demand for its weight-loss injections, even as transaction-related charges prompted a cut to its adjusted profit outlook — revenue growth and earnings guidance moving in opposite directions.

Two scorecards, not one

For Novo, the courtroom and the clinic are separate scorecards. The injunction decision addresses whether Lilly can air the disputed advertising during the dispute; the TRANSCEND-T2D-2 data describe treatment outcomes. Neither resolves the other, and the outcome of the expedited proceeding carries no verdict on the clinical rivalry.

Novo's own scientific calendar is crowded. At The Liver Meeting, running 5–9 November, the company plans presentations on semaglutide and the investigational drug efruxifermin, covering both clinical data and real-world treatment experience. The ObesityWeek congress in Washington follows on 14–17 November, where the investigational candidate CagriSema and experience with the Wegovy pill take centre stage; the programme there comprises 26 contributions, according to the company. None of the announcements contained fresh clinical results, which caps their immediate relevance for any reassessment of the stock.

One concrete finding does stand out. In a post-hoc analysis of REDEFINE-1 presented roughly two weeks ago, women on CagriSema averaged a 25.0% weight loss after 68 weeks, against 3.0% on placebo — a figure that assumed all participants adhered to treatment.

The financial anchor

The next company-specific reference point arrives on 4 November, when Novo publishes results for the first nine months of 2026, followed by a conference call from 13:00 to 14:00 CET. Those numbers will show how the business is actually performing, a question that no single study readout can answer. Announced congress abstracts are not published results, and a lone analysis cannot be translated into a treatment's financial contribution.

Set against Lilly's upgraded sales outlook and its head-to-head win, Novo's competitive position faces scrutiny on several fronts at once. Yet the legal setback is no substitute for operational assessment, and the coming data presentations are no proxy for the earnings print. Keeping the layers apart — litigation, clinical evidence, commercial guidance and Novo's own financials — is the only way to read a November that will be busy on all of them.